Published online Jun 24, 2015. doi: 10.5500/wjt.v5.i2.52
Peer-review started: November 28, 2014
First decision: December 26, 2014
Revised: January 16, 2015
Accepted: April 27, 2015
Article in press: April 29, 2015
Published online: June 24, 2015
Processing time: 203 Days and 21.1 Hours
Ischemia/reperfusion injury is an unavoidable relevant consequence after kidney transplantation and influences short term as well as long-term graft outcome. Clinically ischemia/reperfusion injury is associated with delayed graft function, graft rejection, chronic rejection and chronic graft dysfunction. Ischemia/reperfusion affects many regulatory systems at the cellular level as well as in the renal tissue that result in a distinct inflammatory reaction of the kidney graft. Underlying factors of ischemia reperfusion include energy metabolism, cellular changes of the mitochondria and cellular membranes, initiation of different forms of cell death-like apoptosis and necrosis together with a recently discovered mixed form termed necroptosis. Chemokines and cytokines together with other factors promote the inflammatory response leading to activation of the innate immune system as well as the adaptive immune system. If the inflammatory reaction continues within the graft tissue, a progressive interstitial fibrosis develops that impacts long-term graft outcome. It is of particular importance in kidney transplantation to understand the underlying mechanisms and effects of ischemia/reperfusion on the graft as this knowledge also opens strategies to prevent or treat ischemia/reperfusion injury after transplantation in order to improve graft outcome.
Core tip: In kidney transplantation the ischemia reperfusion injury is a severe unavoidable consequence that may impact the graft outcome. The underlying mechanisms are not completely understood and new findings are continuously being discovered. These involve the biological cellular mechanisms and the gene related response to injury as ischemia and reperfusion. Therapeutically, is extremely important to control this severe complication. Several drugs and strategies are now available and a number of international trials are ongoing. In addition future therapies are now in the pipeline and will be described in this manuscript.